Quantum BioPharma is trading 10.64% up now at $3.64 after September 9, 2026 coverage spotlighted FDA clearance for Lucid-MS to enter Phase 2 testing in progressive multiple sclerosis.
- The treatment is positioned as a potentially first-in-class approach targeting myelin protection and repair.
- The milestone has attracted positive analyst attention as broader U.S. markets trade lower, making this primarily a company-driven move.